Hims & Hers Health, Inc. (HIMS)
| Market Cap | 8.92B |
| Revenue (ttm) | 2.21B |
| Net Income (ttm) | 133.79M |
| Shares Out | 227.65M |
| EPS (ttm) | 0.54 |
| PE Ratio | 73.02 |
| Forward PE | 66.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 22,225,476 |
| Open | 40.00 |
| Previous Close | 40.02 |
| Day's Range | 39.17 - 40.99 |
| 52-Week Range | 23.97 - 72.98 |
| Beta | 2.41 |
| Analysts | Hold |
| Price Target | 44.56 (+13.67%) |
| Earnings Date | Nov 3, 2025 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $44.56, which is an increase of 13.67% from the latest price.
News
A New Market, A New Catalyst: Assessing Hims & Hers' Canadian Opportunity
Hims & Hers Health expands into Canada via Livewell acquisition, targeting a large, underserved weight-loss market. Canadian entry leverages local leadership and expertise, aiming to replicate success...
Hims & Hers launches into Canada as country prepare for generic GLP-1 weight loss drugs
Hims & Hers launched in Canada after announcing the company completed its all-cash acquisition of Canadian digital health provider “Livewell”. The deal comes just one month before generic semaglutide ...
Hims & Hers Now Serving Customers in Canada
MONTREAL--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, is now serving customers in Canada. This entry follows the recent acqui...
Hims & Hers Continues Major International Expansion With Official Entry Into Canada
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform in the United States, is now serving customers in Canada. This entry follows the recent ...
Hims & Hers to Acquire YourBio Health, Pioneer Behind Advanced, Pain-Free Blood Sampling Technology
SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced that it has entered into a definitive agreement to acquire You...
GraniteShares Expands YieldBOOST™ Lineup with Two New ETFs Targeting RIOT Platforms and Hims & Hers Health (RTYY and HMYY)
New York, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- GraniteShares, a one of the leading issuer of exchange-traded funds (ETFs), today announced the launch of two new additions to its growing YieldBOOST ™ ...
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
The regulatory changes surrounding the weight loss treatment industry are having a large impact on Hims & Hers (HIMS 1.83%) stock.
From Hair Loss To GLP-1: Hims & Hers Health Is Quietly Building A 2030 Healthcare Platform
Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product of...
Hims & Hers: The Growth Story Is Outside GLP-1s
Hims & Hers maintains its long-term Buy rating, despite recent stock volatility and slower subscriber growth. HIMS continues to expand its platform beyond GLP-1s, investing heavily in verticalization ...
Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq
Oddity, the maker of Il Makiage and Spoiled Child, launched its third brand Methodiq, a telehealth platform for medical skincare. Methodiq will offer 28 new products, including creams, supplements and...
Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company,” NYSE: HIMS), the leading health and wellness platform, today announced that its Board of Directors has authori...
Hims & Hers names ex-FDA official Deb Autor as first policy chief
Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, the telehealth firm said on Monday.
Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Office...
Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing
Hims & Hers Health, Inc. (NYSE: HIMS) announced the launch of Labs, a new way for customers to understand their overall health and identify ways to improve and maintain it.
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks
Short interest data offers a look into investor sentiment and potential risk within the stock market and can help investors gauge how much skepticism or confidence the market has in a company's future...
Hims & Hers Introduces Labs, a Holistic, In-Depth Testing Experience That Puts Customers in Control of Their Health and Wellness Journeys
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of Labs, a new way for customers to understand their overall...
Hims & Hers Bets on Lab Testing to Boost Growth
The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future health issues.
2 Strong Healthcare Stock Picks for Growth Investors
The health industry offers opportunities beyond the big, well-known names. TransMedics Group boasts a sticky business model that is highly profitable.
2 Quality Healthcare Stocks That Could Build a Strong Foundation for Beginner Investors
These stocks have a lot more to offer than GLP-1 success. Eli Lilly is one of the oldest pharmaceutical companies in the world, is insanely profitable, and boasts a wide range of portfolio stars.
3 Overvalued Stocks to Sell
These are among the most overvalued stocks that Morningstar covers.
Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade)
We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans driving 50% Y/Y revenue growth. Hen...
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Hims & Hers continues to generate strong revenue growth. The company said it was in active discussion with Novo Nordisk to bring back Wegovy to its platform.
Hims & Hers: GLP-1 Partnership Could Unlock Value
Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential at-ho...